Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGeiger Counter Regulatory News (GCL)

Share Price Information for Geiger Counter (GCL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 49.50
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 1.00 (2.041%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 49.50
GCL Live PriceLast checked at -
Geiger Counter is an Investment Trust

To deliver attractive returns to shareholders principally in the form of capital growth, through investment in companies involved in the exploration, development and production of uranium to supply the nuclear power industry.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Annual Overview from QuotedData

1 Dec 2023 10:59

RNS Number : 4138V
Geiger Counter Ltd
01 December 2023
 

 

Geiger Counter Limited - Annual Overview from QuotedData

1st December 2023

Powered up for growth

Geiger Counter (GCL), which invests in companies involved in the exploration, development and production of uranium, is set to benefit from nuclear power's colossal role in decarbonising the global electricity supply. Governments around the world are making nuclear energy (the only source of zero carbon baseload power - the minimum amount of electric power needed to be supplied to the electrical grid at any given time) a cornerstone of the green agenda. 

Existing nuclear reactors' lives are being extended, while Asia drives a global fleet expansion as demand for uranium surges. Meanwhile, a 10-year bear market has restricted investment in any new supply and created a highly supportive backdrop for uranium, with the spot price jumping considerably in recent months. 

At less than 10% of the overall cost of power production, there is little to no demand destruction from higher pricing, which is why GCL's managers believe that there is material further upside to come. GCL's 19.9% discount to net asset value (NAV) seems both unjustified and extremely attractive.

Full Research:

https://quoteddata.com/research/geiger-counter-limited-powered-growth-qd/

This research is also available free on our website www.quoteddata.com where you will also find news, performance data and factsheets on every London listed Investment Company. QuotedData writes and distributes research on a number of quoted companies, facilitates meetings between those companies and existing and potential investors and assists in raising additional capital where required.

NB: Marten & Co was paid to produce this note on Geiger Counter Limited and it is for information purposes only. It is not intended to encourage the reader to deal in the security or securities mentioned in this report. Please read the important information at the back of this note. QuotedData is a trading name of Marten & Co Limited which is authorised and regulated by the Financial Conduct Authority. Marten & Co is not permitted to provide investment advice to individual investors categorised as Retail Clients under the rules of the Financial Conduct Authority.

QUOTEDDATA50 Gresham Street | London EC2V 7AYTel: +44 (0) 20 3691 9430

www.quoteddata.com | research@quoteddata.com | www.martenandco.com

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAEAEAFESKDFFA
Date   Source Headline
13th Jun 20241:35 pmRNSNet Asset Value(s)
13th Jun 202410:30 amRNSShare BuyBack
12th Jun 20242:45 pmRNSNet Asset Value(s)
12th Jun 202411:00 amRNSShare BuyBack
11th Jun 20243:20 pmRNSNet Asset Value(s)
11th Jun 202412:30 pmRNSShare BuyBack
10th Jun 20244:15 pmRNSNet Asset Value(s)
10th Jun 202412:30 pmRNSShare BuyBack
7th Jun 20244:00 pmRNSNet Asset Value(s)
7th Jun 202411:00 amRNSShare BuyBack
6th Jun 20242:45 pmRNSNet Asset Value(s)
6th Jun 202411:30 amRNSShare BuyBack
5th Jun 20243:35 pmRNSNet Asset Value(s)
5th Jun 20242:30 pmRNSShare BuyBack
4th Jun 20244:30 pmRNSNet Asset Value(s)
4th Jun 202411:15 amRNSShare BuyBack
4th Jun 202410:40 amRNSSub Share Rights & Distribution of Rump proceeds
3rd Jun 20244:20 pmRNSNet Asset Value(s)
3rd Jun 20243:10 pmRNSShare BuyBack
31st May 20243:30 pmRNSNet Asset Value(s)
31st May 20241:15 pmRNSShare BuyBack
30th May 20244:45 pmRNSNet Asset Value(s)
30th May 20244:20 pmRNSShare BuyBack
29th May 20243:15 pmRNSNet Asset Value(s)
29th May 20242:20 pmRNSShare Buyback
28th May 20245:00 pmRNSNet Asset Value(s)
24th May 20245:00 pmRNSNet Asset Value(s)
23rd May 20244:10 pmRNSNet Asset Value(s)
22nd May 20243:25 pmRNSNet Asset Value(s)
21st May 20242:40 pmRNSNet Asset Value(s)
20th May 20242:25 pmRNSNet Asset Value(s)
17th May 202411:40 amRNSNet Asset Value(s)
16th May 20241:10 pmRNSNet Asset Value(s)
15th May 20241:55 pmRNSNet Asset Value(s)
14th May 202412:15 pmRNSNet Asset Value(s)
13th May 20241:45 pmRNSNet Asset Value(s)
10th May 20244:05 pmRNSNet Asset Value(s)
10th May 20248:00 amRNSNet Asset Value(s)
9th May 202411:15 amRNSExercise of outstanding Subscription Share Rights
8th May 20245:15 pmRNSNet Asset Value(s)
8th May 20244:45 pmRNSCorrection to Diluted Net Asset Value
7th May 20245:30 pmRNSNet Asset Value(s)
7th May 20241:30 pmRNSNotification in regard to Subscription Rights
7th May 20241:15 pmRNSResult of subscription rights exercise
3rd May 20242:20 pmRNSNet Asset Value(s)
2nd May 20242:45 pmRNSNet Asset Value(s)
1st May 20243:35 pmRNSNet Asset Value(s)
30th Apr 20243:30 pmRNSNet Asset Value(s)
30th Apr 20242:00 pmRNSShare Buyback
29th Apr 202412:45 pmRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.